Jason K Sicklick1,2, Paul T Fanta3,4, Kelly Shimabukuro3,4, Razelle Kurzrock3,4. 1. Center for Personalized Cancer Therapy, San Diego, CA, USA. jsicklick@ucsd.edu. 2. Division of Surgical Oncology, Department of Surgery, University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC 0987, La Jolla, CA, 92093-0987, USA. jsicklick@ucsd.edu. 3. Center for Personalized Cancer Therapy, San Diego, CA, USA. 4. Division of Hematology and Oncology, University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC 0987, La Jolla, 92093-0987, CA, USA.
Abstract
BACKGROUND AND AIMS: Gallbladder carcinoma is a rare, aggressive malignancy of the biliary tract associated with a poor prognosis. Despite the deployment of targeted therapies that have demonstrated marked survival benefits in many tumor types, traditional cytotoxic chemotherapy has remained the mainstay of treatment for unresectable and metastatic gallbladder cancer. METHODS: Systematic review of ongoing and prior clinical studies shows a paucity of biomarker-driven therapeutic trials using targeted agents in gallbladder cancer. In fact, over the past 6 years, of the 38 therapeutic biliary tract protocols listed on clinicaltrials.gov, only 6 (21 %) utilized targeted therapies based upon tumor biomarkers or genomics. Now that we have entered the era of next-generation sequencing and precision medicine, we are beginning to identify common and specific genetic alterations in gallbladder carcinomas. RESULTS: A review of the literature reveals alterations in ARID1A, BRAF, CDKN2A/B, EGFR, ERBB2-4, HKN-RAS, PIK3CA, PBRM1, and TP53. Given the widespread use of tumor genomic profiling and the fact that most of the aforementioned alterations are pharmacologically tractable, these observations suggest the potential for new therapeutic strategies in this aggressive malignancy. CONCLUSIONS: Taken together, further understanding of the genomic landscape of gallbladder cancer coupled with biomarker-driven clinical trials that match therapies to targets are urgently needed.
BACKGROUND AND AIMS: Gallbladder carcinoma is a rare, aggressive malignancy of the biliary tract associated with a poor prognosis. Despite the deployment of targeted therapies that have demonstrated marked survival benefits in many tumor types, traditional cytotoxic chemotherapy has remained the mainstay of treatment for unresectable and metastatic gallbladder cancer. METHODS: Systematic review of ongoing and prior clinical studies shows a paucity of biomarker-driven therapeutic trials using targeted agents in gallbladder cancer. In fact, over the past 6 years, of the 38 therapeutic biliary tract protocols listed on clinicaltrials.gov, only 6 (21 %) utilized targeted therapies based upon tumor biomarkers or genomics. Now that we have entered the era of next-generation sequencing and precision medicine, we are beginning to identify common and specific genetic alterations in gallbladder carcinomas. RESULTS: A review of the literature reveals alterations in ARID1A, BRAF, CDKN2A/B, EGFR, ERBB2-4, HKN-RAS, PIK3CA, PBRM1, and TP53. Given the widespread use of tumor genomic profiling and the fact that most of the aforementioned alterations are pharmacologically tractable, these observations suggest the potential for new therapeutic strategies in this aggressive malignancy. CONCLUSIONS: Taken together, further understanding of the genomic landscape of gallbladder cancer coupled with biomarker-driven clinical trials that match therapies to targets are urgently needed.
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245
Authors: Al B Benson; Michael I D'Angelica; Thomas A Abrams; Chandrakanth Are; P Mark Bloomston; Daniel T Chang; Bryan M Clary; Anne M Covey; William D Ensminger; Renuka Iyer; R Kate Kelley; David Linehan; Mokenge P Malafa; Steven G Meranze; James O Park; Timothy Pawlik; James A Posey; Courtney Scaife; Tracey Schefter; Elin R Sigurdson; G Gary Tian; Jean-Nicolas Vauthey; Alan P Venook; Yun Yen; Andrew X Zhu; Karin G Hoffmann; Nicole R McMillian; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2014-08 Impact factor: 11.908
Authors: R Buzzoni; S Pusceddu; E Bajetta; F De Braud; M Platania; C Iannacone; M Cantore; A Mambrini; A Bertolini; O Alabiso; A Ciarlo; C Turco; V Mazzaferro Journal: Ann Oncol Date: 2014-05-14 Impact factor: 32.976
Authors: J W Valle; H Wasan; P Johnson; E Jones; L Dixon; R Swindell; S Baka; A Maraveyas; P Corrie; S Falk; S Gollins; F Lofts; L Evans; T Meyer; A Anthoney; T Iveson; M Highley; R Osborne; J Bridgewater Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640
Authors: Yael Berger; Brianne J Sullivan; Natasha L Leigh; Eliahu Y Bekhor; Pooja Dhorajiya; Malary Mani; Deepa R Magge; Da Eun Cha; Umut Sarpel; Spiros P Hiotis; Daniel M Labow; Stephen C Ward; Benjamin J Golas; Noah A Cohen Journal: Ann Surg Oncol Date: 2022-04-18 Impact factor: 5.344
Authors: Ashwyn K Sharma; Jorge de la Torre; Nikki S IJzerman; Thomas L Sutton; Beiqun Zhao; Tahsin M Khan; Sudeep Banerjee; Christina Cui; Vi Nguyen; Maha Alkhuziem; Petur Snaebjornsson; Hester van Boven; Annemarie Bruining; Chih-Min Tang; Hyunho Yoon; Alexa De la Fuente; Shumei Kato; Hitendra Patel; Michael C Heinrich; Christopher L Corless; Santiago Horgan; Adam M Burgoyne; Paul Fanta; Jill P Mesirov; Andrew M Blakely; Jeremy L Davis; Skye C Mayo; Winan J van Houdt; Neeltje Steeghs; Jason K Sicklick Journal: Clin Cancer Res Date: 2021-10-01 Impact factor: 12.531